Literature DB >> 33958155

Developing Precision Medicine for Bladder Cancer.

Brendan J Guercio1, Gopa Iyer2, Jonathan E Rosenberg3.   

Abstract

The hallmark of precision medicine involves tailoring the treatment to the patient and/or tumor-specific biomarkers. Candidate biomarkers in bladder cancer are abundant, but few have been validated in clinical practice. Significant obstacles to precision medicine in bladder cancer include the limited predictive value of candidate biomarkers, lack of standardization in biomarker assessment, heterogeneity in biomarker expression and function, and limited insight into the biologic factors that influence biomarker expression and predictive capacity. This review summarizes key biomarkers explored in bladder cancer and outlines innovative trial designs to approach these obstacles.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Bladder cancer; Chemotherapy; Immunotherapy; Precision medicine; Targeted therapy; Urothelial carcinoma

Mesh：

Substances：

Year:  2021        PMID： 33958155      PMCID： PMC8108703          DOI： 10.1016/j.hoc.2021.02.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   2.861


  86 in total

1.  Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Authors:  Sumanta K Pal; Jonathan E Rosenberg; Jean H Hoffman-Censits; Raanan Berger; David I Quinn; Matthew D Galsky; Juergen Wolf; Christian Dittrich; Bhumsuk Keam; Jean-Pierre Delord; Jan H M Schellens; Gwenaelle Gravis; Jacques Medioni; Pablo Maroto; Virote Sriuranpong; Chaiyut Charoentum; Howard A Burris; Viktor Grünwald; Daniel Petrylak; Ulka Vaishampayan; Eliahu Gez; Ugo De Giorgi; Jae-Lyun Lee; Jens Voortman; Sumati Gupta; Sunil Sharma; Amir Mortazavi; David J Vaughn; Randi Isaacs; Katie Parker; Xueying Chen; Kun Yu; Dale Porter; Diana Graus Porta; Dean F Bajorin
Journal:  Cancer Discov       Date:  2018-05-30       Impact factor: 39.397

2.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

Review 3.  Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Authors:  Qiang Li; Aditya Bagrodia; Eugene K Cha; Jonathan A Coleman
Journal:  Curr Urol Rep       Date:  2016-02       Impact factor: 3.092

4.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Authors:  John D Hainsworth; Funda Meric-Bernstam; Charles Swanton; Herbert Hurwitz; David R Spigel; Christopher Sweeney; Howard Burris; Ron Bose; Bongin Yoo; Alisha Stein; Mary Beattie; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2018-01-10       Impact factor: 44.544

5.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Authors:  Stéphane Oudard; Stéphane Culine; Yann Vano; François Goldwasser; Christine Théodore; Thierry Nguyen; Eric Voog; Eugeniu Banu; Annick Vieillefond; Franck Priou; Gaël Deplanque; Gwenaëlle Gravis; Alain Ravaud; Jean Michel Vannetzel; Jean-Pascal Machiels; Xavier Muracciole; Marie-France Pichon; Jacques-Olivier Bay; Reza Elaidi; Corine Teghom; François Radvanyi; Philippe Beuzeboc
Journal:  Eur J Cancer       Date:  2014-11-15       Impact factor: 9.162

6.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Authors:  Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

Authors:  David J McConkey; Woonyoung Choi; Yu Shen; I-Ling Lee; Sima Porten; Surena F Matin; Ashish M Kamat; Paul Corn; Randall E Millikan; Colin Dinney; Bogdan Czerniak; Arlene O Siefker-Radtke
Journal:  Eur Urol       Date:  2015-09-03       Impact factor: 20.096

8.  A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

Authors:  G K Philips; S Halabi; B L Sanford; D Bajorin; E J Small
Journal:  Ann Oncol       Date:  2009-01-23       Impact factor: 32.976

9.  Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.

Authors:  Noura J Choudhury; Alexa Campanile; Tatjana Antic; Kai Lee Yap; Carrie A Fitzpatrick; James L Wade; Theodore Karrison; Walter M Stadler; Yusuke Nakamura; Peter H O'Donnell
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

10.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Authors:  Shanu Modi; Cristina Saura; Toshinari Yamashita; Yeon Hee Park; Sung-Bae Kim; Kenji Tamura; Fabrice Andre; Hiroji Iwata; Yoshinori Ito; Junji Tsurutani; Joohyuk Sohn; Neelima Denduluri; Christophe Perrin; Kenjiro Aogi; Eriko Tokunaga; Seock-Ah Im; Keun Seok Lee; Sara A Hurvitz; Javier Cortes; Caleb Lee; Shuquan Chen; Lin Zhang; Javad Shahidi; Antoine Yver; Ian Krop
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245
View more
  1 in total

1.  Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.

Authors:  Jiale Sun; Wenchang Yue; Jiawei You; Xuedong Wei; Yuhua Huang; Zhixin Ling; Jianquan Hou
Journal:  Front Oncol       Date:  2021-09-07       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.